Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Reg. 34 (1) Annual Report.

 Pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), please find enclosed the Annual Report and Notice convening the 44th Annual General Meeting of the Company, including the Business Responsibility and Sustainability Report, for the financial year 2022-23 which is scheduled to be held on Thursday, August 31, 2023 at 03:30 p.m. (IST) through video conference or other audio-visual means, in compliance with relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India ('SEBI'). The aforesaid Annual Report and AGM Notice are also being uploaded on the Company's Website www.jagsonpal.com and the website of National Securities Depository Limited at www.evoting.nsdl.com.
09-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Intimation Of Annual General Meeting And Record Date

 Pursuant to Regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has fixed Monday, August 21, 2023, as the Record Date for determining the entitlement of Members to dividend for the financial year ended March 31, 2023.
08-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed copies of the newspaper advertisement for 44th AGM of the Company to be held through Video Conferencing (VC)/Other Audio Visual Means(OVAM) on August 31, 2023. The advertisement appeared in Business Standard in (English language) and Business Standard in (Hindi language).
05-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provisions of Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed extract copies of newspaper published on August 04, 2023.
04-08-2023
Bigul

Q1FY24 Quarterly Result Announced for Jagsonpal Pharmaceuticals Ltd.

 Jagsonpal Pharmaceuticals announced Q1FY24 results: Q1FY24 vs Q1FY23: Revenues: Rs 602 million vs Rs 606 million Operating EBITDA: Rs 129 million vs Rs 91 million EBITDA Margin: 21.4% vs 15.0% PAT: Rs 75 million vs Rs 29 million Q1FY24 vs Q4FY23: Revenues: Rs 602 million vs Rs 555 million Operating EBITDA: Rs 129 million vs Rs 94 million EBITDA Margin: 21.4% vs 16.9% PAT: Rs 75 million vs Rs 56 million Commenting on the company’s performance, Manish Gupta, Managing Director, stated, “The quarter gone by was significant in the journey of Jagsonpal as we reorganized our sales force for sharper doctor alignment as well as creating headroom for new product introductions. We have now transitioned to 3 operating divisions from 2, with two of them focused extensively on women care products and one on pain management. We maintained our quarterly sales in-line with Q1FY23 but with improved profitability even as the sales team reorganization was underway. With operating EBITDA at Rs 129 million, our operating margin stood at 21.4%, reflecting a 640 bps improvement over last year. Our net profits grew 158% to Rs 75 million.” Result PDF
03-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed Press release for the quarter ended June 30, 2023
02-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023

 Kindly find enclosed the Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report
02-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter ended June 30, 2023.
02-08-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Consider And Approve, Inter-Alia, The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2023.

 JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited ('the Company') is scheduled to be held on Wednesday, August 02, 2023 to consider and approve, inter-alia, the Unaudited Financial Results of the Company for the quarter ended June 30, 2023.
25-07-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 we are enclosing herewith copy of the Certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company , for the quarter ended June 30, 2023.
11-07-2023
Next Page
Close

Let's Open Free Demat Account